Search Results

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II

Authors: Garrison, Louis P.; Mansley, Edward C.; Abbott, Thomas A.; Bresnahan, Brian W.; Hay, Joel W.; Smeeding, James

Source: Value in Health, Volume 13, Number 1, January/February 2010 , pp. 8-13(6)

Publisher: Blackwell Publishing

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report—Part III

Authors: Mansley, Edward C.; Carroll, Norman V.; Chen, Kristina S.; Shah, Nilay D.; Piech, Catherine Tak; Hay, Joel W.; Smeeding, James

Source: Value in Health, Volume 13, Number 1, January/February 2010 , pp. 14-17(4)

Publisher: Blackwell Publishing

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report—Part VI

Authors: Shi, Lizheng; Hodges, Meredith; Drummond, Michael; Ahn, Jeonghoon; Li, Shu Chuen; Hu, Shanlian; Augustovski, Federico; Hay, Joel W.; Smeeding, Jim

Source: Value in Health, Volume 13, Number 1, January/February 2010 , pp. 28-33(6)

Publisher: Blackwell Publishing

Cost-effectiveness research might mislead policy decision making

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 592, 2009-11-28 , pp. 8-8(1)

Publisher: Adis International

Evaluation and justification of clinical pharmacy services

Authors: Anderson, Scott V; Schumock, Glen T

Source: Expert Review of Pharmacoeconomics and Outcomes Research, Volume 9, Number 6, December 2009 , pp. 539-545(7)

Publisher: Expert Reviews

Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part I

Authors: Berger, Marc L.; Mamdani, Muhammad; Atkins, David; Johnson, Michael L.

Source: Value in Health, Volume 12, Number 8, November/December 2009 , pp. 1044-1052(9)

Publisher: Blackwell Publishing

Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part II

Authors: Cox, Emily; Martin, Bradley C.; Van Staa, Tjeerd; Garbe, Edeltraut; Siebert, Uwe; Johnson, Michael L.

Source: Value in Health, Volume 12, Number 8, November/December 2009 , pp. 1053-1061(9)

Publisher: Blackwell Publishing

The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report

Authors: McGhan, William F.; Al, Maiwenn; Doshi, Jalpa A.; Kamae, Isao; Marx, Steven E.; Rindress, Donna

Source: Value in Health, Volume 12, Number 8, November/December 2009 , pp. 1086-1099(14)

Publisher: Blackwell Publishing

Growing Application of Pharmacoeconomics and Outcomes Research in Health-Care Decision-Making in the Asia-Pacific Region

Authors: Yang, Bong-min; Lee, Kenneth

Source: Value in Health, Volume 12, Supplement 3, November/December 2009 , pp. S1-S2(1)

Publisher: Blackwell Publishing

The Current Capacity and Future Development of Economic Evaluation for Policy Decision-Making: A Survey among Researchers and Decision-Makers in Thailand

Authors: Chaikledkaew, Usa; Lertpitakpong, Chanida; Teerawattananon, Yot; Thavorncharoensap, Montarat; Tangcharoensathien, Viroj

Source: Value in Health, Volume 12, Supplement 3, November/December 2009 , pp. S31-S35(1)

Publisher: Blackwell Publishing

Adjusting for health-related QOL does not appear to substantially affect cost per life year (LY) ratios for most cancer studies

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 6-6(1)

Publisher: Adis International

Economic analyses of aromatase inhibitors that are sponsored by pharmaceutical companies are less likely to report unfavourable results

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 13-13(1)

Publisher: Adis International

Biosimilars of tumour necrosis factor-α (TNF-α) inhibitors will erode $9.6 billion in brand sales

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 14-14(1)

Publisher: Adis International

Gastric cancer drug market to grow through targeted therapies

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 14-14(1)

Publisher: Adis International

China to cut prices on over 2300 essential medicines

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 590, 2009-10-31 , pp. 10-10(1)

Publisher: Adis International

A Cost-Effectiveness Analysis to Illustrate the Impact of Cost Definitions on Results, Interpretations and Comparability of Pharmacoeconomic Studies in the US

Author: Tunis, Sandra L.

Source: PharmacoEconomics, Volume 27, Number 9, 1 September 2009 , pp. 735-744(10)

Publisher: Adis International

Leading pharmaceutical markets in Latin America are set to grow by 9.9% per annum on average till 2014

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 587, 2009-09-19 , pp. 9-9(1)

Publisher: Adis International

Varenicline takes the top spot in Belgium

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 588, 2009-10-03 , pp. 9-9(1)

Publisher: Adis International

Novel obesity drugs, oncology biosimilars to impact markets

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 588, 2009-10-03 , pp. 11-11(1)

Publisher: Adis International

Pharmacoeconomics: principles and relevance to the activities of drug and therapeutics committees

Authors: Hughes, Dyfrig; Reynolds, D John M

Source: Clinical Medicine, Journal of the Royal College of Physicians, Volume 9, Number 5, October 2009 , pp. 490-492(3)

Publisher: Royal College of Physicians